GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,640.00
Bid: 1,637.50
Ask: 1,638.00
Change: -10.50 (-0.64%)
Spread: 0.50 (0.031%)
Open: 1,650.50
High: 1,658.50
Low: 1,627.50
Prev. Close: 1,650.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

Fri, 17th May 2024 08:56

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

The FTSE 100 index opened down 13.93 points, 0.2%, at 8,424.72. The FTSE 250 was down 36.70 points, 0.2%, at 20,786.14, and the AIM All-Share was down 0.43 of a point, 0.1%, at 792.07.

The Cboe UK 100 was down 0.1% at 841.06, the Cboe UK 250 was down 0.1% at 18,132.09, and the Cboe Small Companies was up 0.1% at 16,315.05.

In European equities on Friday, the CAC 40 in Paris was down 0.3%, while the DAX 40 in Frankfurt was down 0.4%.

In the US on Thursday, Wall Street ended lower, with the Dow Jones Industrial Average down 0.1%, the S&P 500 down 0.2% and the Nasdaq Composite down 0.3%.

Wall Street had a see-saw session on Thursday, with the Dow Jones notching another landmark in a record breaking week. Before closing lower, the Dow had set a fresh all-time high of 40,051.05.

In China on Friday, the Shanghai Composite was up 1.0%, while the Hang Seng index in Hong Kong was up 1.1%.

Chinese industrial production picked up in April but consumption slowed, official figures showed, as woes in the property sector and elsewhere continued to weigh on economic recovery.

Industrial output rose 6.7% on-year last month, according to the National Bureau of Statistics, building on a 4.5% increase in March. The figure was higher than the 5.5% tipped in a Bloomberg forecast of economists.

However, retail sales growth – China's key gauge of consumer spending – continued to slow, expanding just 2.3% – down from 3.1% in March and lower than forecasts.

"The story of this month’s data is that of prevailing caution by households and the private sector, as retail sales and fixed asset investment came in weaker than expected," said ING economist Lynn Song.

In Japan on Friday, the Nikkei 225 index in Tokyo was down 0.3%. The S&P/ASX 200 in Sydney closed down 0.9%.

The pound was quoted at USD1.2664 early on Friday in London, down compared to USD1.2671 at the equities close on Thursday. The euro stood at USD1.0862, lower against USD1.0870. Against the yen, the dollar was trading at JPY155.77, higher compared to JPY155.26.

In the FTSE 100, Land Securities lost 1.4%.

Land Securities reported that revenue rose to GBP824 million in the year ended March 31, up from GBP791 million a year earlier. Pretax loss in the year narrowed to GBP341 million from GBP622 million.

Land Securities announced a higher total dividend of 39.6p, up 2.6% from 38.6p.

"Our continued operational outperformance, with rising occupancy and positive rental uplifts in retail and London, is driving robust like-for-like rental income growth and demonstrates the importance of owning and operating the best-in-class real estate," said Chief Executive Mark Allan.

GSK lost 0.7%, whilst Haleon was down 0.6%.

GSK said it has agreed to sell its remaining stake in Haleon, the consumer healthcare firm it spun out almost two years ago.

Brentford, London-based GSK said it has agreed to sell its 4.2% stake, around 385 million shares, in Surrey-based Haleon, which spun off from GSK in July 2022. The shares are priced at 324 pence each, raising GBP1.25 billion in total proceeds in the placing to institutional investors.

"Following settlement of the placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon," GSK added.

On London's AIM, Eqtec plummeted 18%.

The Cork, Ireland-based thermochemical conversion technology company said no funds have been received from Verde in regards to its GBP1.5 million subscription agreement. Therefore, it has terminated its agreement with Verde.

Cornish Metals rose 12%.

The Vancouver-based mineral exploration company noted the recent decline in its share price. Over the last five days, the stock has plummeted 34%.

Cornish Metals reassured investors and said that "it is unaware of any operational or corporate reason for the price movement."

Brent oil was quoted at USD83.57 a barrel early in London on Friday, up from USD83.05 late Thursday. Gold was quoted at USD2,383.50 an ounce, up against USD2,381.33.

Still to come on Friday's economic calendar, there is a eurozone inflation reading at 1000 BST.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
3 Jun 2024 17:20

European shares kick-off June on a high note in anticipation of ECB rate cut

GSK tumbles as Zantac lawsuits allowed to proceed

*

Read more
3 Jun 2024 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
3 Jun 2024 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
3 Jun 2024 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
3 Jun 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
3 Jun 2024 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
3 Jun 2024 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
3 Jun 2024 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
3 Jun 2024 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.